


Rapid AAV pre-formulation screening using a commercially available buffer kit & minimal sample requirement



Philipp Beck, Astrid Stockinger, Sonya Schermann

P095

Material constraints are a limiting factor in early stage AAV gene therapy development programs. This is especially true for initial, broad formulation studies, that consume substantial amounts of material and time. We established a **low-volume, high-throughput pre-formulation screening** approach that requires only very low sample amounts and provides results within two days.

Starting with only **4 mL** of an AAV vector at **2-4E12 vg/mL**, we used a commercially available buffer kit containing **96 FDA/EMA-approved biologics formulations** to generate thermal capsid (nanoDSF) and inter-particle (DLS) stability data. Only **40 µL** of sample per condition are sufficient to generate a starting point for focused buffer screenings.

Capsid stability




nanoDSF

Colloidal stability




DLS

Inversed relationship: lower pH → higher melting point




Capsid stability of the serotype used in the study was found to be **strongly influenced by pH**, whereas other formulation parameters & excipients had negligible effects on AAV melting temperature (T_m). Thermal stability increased with decreasing pH, with up to +15 °C improvement in T_m compared to the basic formulation of the starting material.

Adjustment of ionic strength has no influence on melting temperature




The pH range of 4.5 – 6.8 was more closely evaluated in a focused screening using acetate, histidine, citrate (all 40 mM) and PBS: at pH < 6.7, unfolding temperatures are > 80 °C (A/B). This pattern occurs independent of the buffer substance used as observed for citrate and PBS in B. Importantly, additional NaCl did not influence the unfolding temperatures (A/B) and thus the thermal stability of the capsid is not affected by this change in ionic strength.


Ionic strength dictates resistance towards aggregation upon heat stress



- Colloidal status of formulations was determined directly after mixing AAV with the buffer kit (above). This already demonstrated that some of the formulations are not suitable (high polydispersity index, PDI).
- Monitoring temperature-induced onset of AAV aggregation (T_{onset}) showed that ionic strength is a main contributor to colloidal stability upon heat stress (right), confirming published data^[1] and validating our platform.




Adjustment of ionic strength leads to higher aggregation temperature with some buffers



- As shown in the box above & left, pH < 7 and ionic strength > 200 mM confers colloidal and thermal stability.
- Next, the pH range of 4.5 – 6.8 was more closely evaluated in a focused screening using acetate, histidine, citrate and PBS. Addition of 150 mM NaCl to buffers lead to an increase in T_{onset} (A/B). Citrate is a special case since the ionic strength of the 40 mM citrate buffer is already high enough to result in a T_{onset} > 60°C (except for one likely outlier at pH at pH 6.2 (B).

Ionic strength threshold: NaCl-titration

A closer examination of the effect of ionic strength by addition of NaCl to 40 mM Acetate at pH 5.5 was performed: A threshold exists in the 200–225 mM range above which further increase of ionic strength does not increase the colloidal stability of AAV in the formulation during heat stress.



Poster downloads



Summary

- Using nanoDSF, we showed that conformational stability is strongly influenced by pH, whereas other formulation parameters & excipients had negligible effects on AAV melting temperature. Specifically, thermal stability increased with decreasing pH, with up to +15 °C improvement in T_m compared to the basic formulation of the starting material.
- We demonstrated that T_{onset} could be increased by up to +25 °C compared to the starting material and that a minimum ionic strength-level (around 200 mM) is required for colloidal stabilization which is in line with published data.^[1] Ionic strength was found to be the **only major contributor** to colloidal stability.
- The data provides a solid basis to inform further rational formulation development. The **approach is capsid agnostic**: it can be applied to **any AAV serotype** or other novel modalities based on **protein nanoparticles**.

[1] JF Wright et al. "Identification of Factors that Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent Its Occurrence during Vector Purification and Formulation" Molecular Therapy, Vol. 12, No. 1, 2005